✦ LIBER ✦

Role of raloxifene in breast cancer prevention in postmenopausal women: Clinical evidence and potential mechanisms of action

✍ Scribed by Michael B. Sporn; Sherie A. Dowsett; John Mershon; Henry U. Bryant

Book ID: 117321640
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 787 KB
Volume: 26
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(04)90127-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Raloxifene: potential role in breast can

Raloxifene: potential role in breast cancer prevention

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Effects of clomiphene and raloxifene on

Effects of clomiphene and raloxifene on gonadotrophin secretion in postmenopausal women: evidence of nongenomic action

✍ A. Garas; G. Trypsianis; A. Kallitsaris; S. Milingos; I. E. Messinis 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

1–2 Effects of Raloxifene on Cardiovascu

1–2 Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women

✍ Bevers, T.B. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Effect of raloxifene on IGF-I and IGFBP-

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

✍ Torrisi, R; Baglietto, L; Johansson, H; Veronesi, G; Bonanni, B; Guerrieri-Gonza 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 52 KB

Cost-effectiveness of raloxifene and hor

Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk

✍ Katrina Armstrong; Tze-Ming Chen; Daniel Albert; Thomas C Randall; J Sanford Sch 📂 Article 📅 2001 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 95 KB

Arzoxifene for prevention of fractures a

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

✍ Steven R Cummings; Michael McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 97 KB

## Abstract Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined